Bank of America invests ₹2,400 crore annually in employee weight-loss medication
Bank of America CEO Brian Moynihan revealed that the company now spends more than $250 million, or approximately ₹2,400 crore, every year to provide GLP-1 weight-loss drugs to its workforce. This cost, which was non-existent five years ago, currently makes up 13% of the bank's total $2 billion healthcare expenditure. Moynihan defended the spending as a "good investment," pointing to the positive long-term health outcomes these medications may offer.
by shortkt.com✓